Castle Biosciences (NASDAQ:CSTL) Stock: Insider Tobin Juvenal Sells 2,828 Shares

Castle Biosciences, Inc. (NASDAQ:CSTL) insider Tobin Juvenal sold 2,828 shares of the business’s stock in a transaction dated Wednesday, November 11th. The stock was sold at an average price of $35.04, for a total transaction of $99,093.12. Following the transaction, the insider owned 32,737 shares in the company, valued at approximately $1,147,104.48. This trade represents a 7.95% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Castle Biosciences Stock Performance

NASDAQ:CSTL traded up $0.51 during mid-day trading on Thursday, reaching $34.50. The stock had a trading volume of 440,800 shares, compared to its average volume of 398,699. The company has a debt-to-equity ratio of 0.01, a quick ratio of 5.12 and a current ratio of 5.28. The firm has a market capitalization of $1.06 billion, a price-to-earnings ratio of -44.81 and a beta of 1.00. Castle Biosciences, Inc. has a twelve month low of $17.72 and a twelve month high of $44.28. The business has a 50 day simple moving average of $34.30 and a 200 day simple moving average of $28.42.

Castle Biosciences (NASDAQ:CSTL) last released its earnings results on Thursday, November 5th. The company reported ($0.13) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.35) by $0.22. The company had revenue of $101.95 million for the quarter, compared to analysts’ expectations of $92.76 million. Castle Biosciences had a negative return on equity of 4.89% and a negative net margin of 6.10%. On average, analysts expect that Castle Biosciences, Inc. will post -0.83 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Castle Biosciences

Hedge funds and other institutional investors have recently bought and sold shares of the company. Allworth Financial LP boosted its position in Castle Biosciences by 255.3% during the third quarter. Allworth Financial LP now owns 938 shares of the company’s stock worth $33,000 after purchasing an additional 674 shares in the last quarter. NFSG Corp purchased a new position in shares of Castle Biosciences in the third quarter valued at $36,000. Global Retirement Partners LLC purchased a new position in shares of Castle Biosciences in the second quarter valued at $26,000. Mirae Asset Global Investments Co. Ltd. acquired a new position in shares of Castle Biosciences during the 3rd quarter worth $55,000. Finally, Quantbot Technologies LP acquired a new position in shares of Castle Biosciences during the 2nd quarter worth $62,000. 92.60% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

CSTL has been the topic of a number of recent analyst reports. Mizuho started coverage on Castle Biosciences in a report on Thursday, October 29th. They set an “outperform” rating and a $60.00 price objective on the stock. Wall Street Zen upgraded shares of Castle Biosciences from a “hold” rating to a “buy” rating in a research report on Sunday, November 1st. Robert W. Baird boosted their target price on shares of Castle Biosciences from $39.00 to $41.00 and gave the stock an “outperform” rating in a research report on Monday. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Castle Biosciences in a research note on Thursday, October 29th. Finally, KeyCorp increased their price target on shares of Castle Biosciences from $35.00 to $40.00 and gave the company an “overweight” rating in a report on Friday, November 6th. One research analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $46.50.

Castle Biosciences Company Profile

Castle Biosciences, Inc. is a molecular diagnostics company that develops and commercializes tests intended to help physicians make personalized treatment and care decisions. Its tests analyze biological features of tissue to provide information about disease behavior and patient risk. The company’s portfolio includes DecisionDx tests for conditions such as cutaneous melanoma, cutaneous squamous cell carcinoma and uveal melanoma. It also offers TissueCypher, a test designed to assess progression risk in patients with Barrett’s esophagus.